| Nicole Lavonne Malstrom, | |
|
68 N 180 W, Ephraim, UT 84627-2130 | |
| (435) 283-9932 | |
| (435) 283-4920 |
| Full Name | Nicole Lavonne Malstrom |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 68 N 180 W, Ephraim, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043813090 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Lavonne Malstrom, 68 N 180 W, Ephraim, UT 84627-2130 Ph: (435) 283-9932 | Nicole Lavonne Malstrom, 68 N 180 W, Ephraim, UT 84627-2130 Ph: (435) 283-9932 |
News Archive
New data from an ongoing Phase III trial revealed today at The International Liver Congress 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT).
The diagnosis of myelodysplastic syndrome, a blood cancer, often causes confusion. While some patients can be treated with repeated blood transfusions, others require chemotherapy, leaving some uncertainty about whether the syndromes actually are cancer.
James Bond had his reasons for ordering his martinis "shaken, not stirred." Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.
LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 8 days ago
Mr. Scott Winters, Counselor Medicare: Not Enrolled in Medicare Practice Location: 90 N 161 W, Ephraim, UT 84627 Phone: 435-283-9934 | |
Crystal Alvarez, Counselor Medicare: Not Enrolled in Medicare Practice Location: 152 N 400 W, Ephraim, UT 84627 Phone: 435-283-8400 Fax: 435-283-8401 | |
Jolene Blackburn, CPCI Counselor Medicare: Not Enrolled in Medicare Practice Location: 390 W 100 N, Ephraim, UT 84627 Phone: 435-283-4065 Fax: 435-283-5387 | |
Susan Diane Nielson, RN Counselor Medicare: Not Enrolled in Medicare Practice Location: 390 W 100 N, Ephraim, UT 84627 Phone: 435-283-4065 Fax: 435-283-5387 | |
Jonatan Lopez Mancilla, Counselor Medicare: Not Enrolled in Medicare Practice Location: 390 W 100 N, Ephraim, UT 84627 Phone: 435-283-4065 Fax: 435-283-8401 | |
Francis Russell Beck Jr., LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 338 S 300 E, Ephraim, UT 84627 Phone: 435-283-4305 |